PPARG and metabolic dysfunction-associated steatohepatitis: Consistently, adenovirus-mediated overexpression of PPARγ or treatment with rosiglitazone, a PPARγ agonist, alleviates inflammatory responses and liver fibrosis in a NASH murine model [15,16].